WHAT IS THE TRUE CLINICAL-SIGNIFICANCE OF PLASMA-PROTEIN BINDING DISPLACEMENT INTERACTIONS

[11] Lima J.J., Disopyramide, Applied pharmacokinetics. Principles of therapeutic drug monitoring, (1986)

[12] Jack D.B., Handbook of clinical pharmacokinetic data, pp. 1-132, (1992)

[13] Miners J.O., Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid, Clin Pharmacokinet, 17, (1989)

[14] Seller E.M., Koch-Weser J., Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate, N Engl J Med, 283, (1970)

[15] Udal J.A., Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance, Ann Intern Med, 81, (1974)

[16] Aarons L.J., Rowland M., Kinetics of drug displacement interactions, J Pharmacokinet Biopharm, 9, (1981)

[17] Wilkinson G.R., Clearance, Pharmacol Rev, 39, pp. 1-47, (1987)

[18] Morgan D.J., Smallwood R.A., Clinical significance of pharmacokinetic models of hepatic elimination, Clin Pharmacokinet, 18, pp. 61-76, (1990)

[19] Nation R.L., Evans A.M., Milne R.W., Pharmacokinetic drug interactions with phenytoin (part I), Clin Pharmacokinet, 18, pp. 37-60, (1990)

[20] Dahlqvist R., Borga O., Rane A., Et al., Decreased plasma protein binding of phenytoin in patients on valproic acid, Br J Clin Pharmacol, 8, (1979)

[11] Lima J.J., Disopyramide, Applied pharmacokinetics. Principles of therapeutic drug monitoring, (1986)

[12] Jack D.B., Handbook of clinical pharmacokinetic data, pp. 1-132, (1992)

[13] Miners J.O., Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid, Clin Pharmacokinet, 17, (1989)

[14] Seller E.M., Koch-Weser J., Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate, N Engl J Med, 283, (1970)

[15] Udal J.A., Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance, Ann Intern Med, 81, (1974)

[16] Aarons L.J., Rowland M., Kinetics of drug displacement interactions, J Pharmacokinet Biopharm, 9, (1981)

[17] Wilkinson G.R., Clearance, Pharmacol Rev, 39, pp. 1-47, (1987)

[18] Morgan D.J., Smallwood R.A., Clinical significance of pharmacokinetic models of hepatic elimination, Clin Pharmacokinet, 18, pp. 61-76, (1990)

[19] Nation R.L., Evans A.M., Milne R.W., Pharmacokinetic drug interactions with phenytoin (part I), Clin Pharmacokinet, 18, pp. 37-60, (1990)

[20] Dahlqvist R., Borga O., Rane A., Et al., Decreased plasma protein binding of phenytoin in patients on valproic acid, Br J Clin Pharmacol, 8, (1979)